BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25117093)

  • 1. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.
    Davitt K; Babcock BD; Fenelus M; Poon CK; Sarkar A; Trivigno V; Zolkind PA; Matthew SM; Grin'kina N; Orynbayeva Z; Shaikh MF; Adler V; Michl J; Sarafraz-Yazdi E; Pincus MR; Bowne WB
    Ann Clin Lab Sci; 2014; 44(3):241-8. PubMed ID: 25117093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Cancer Tumor Cell Necrosis of Epithelial Ovarian Cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes.
    Thadi A; Gleeson EM; Khalili M; Shaikh MF; Goldstein E; Morano WF; Daniels LM; Grandhi N; Glatthorn H; Richard SD; Campbell PM; Sarafraz-Yazdi E; Pincus MR; Bowne WB
    Ann Clin Lab Sci; 2020 Sep; 50(5):611-624. PubMed ID: 33067207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells.
    Thadi A; Lewis L; Goldstein E; Aggarwal A; Khalili M; Steele L; Polyak B; Seydafkan S; Bluth MH; Ward KA; Styler M; Campbell PM; Pincus MR; Bowne WB
    Anticancer Res; 2020 Sep; 40(9):4857-4867. PubMed ID: 32878773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells.
    Bowne WB; Sookraj KA; Vishnevetsky M; Adler V; Sarafraz-Yazdi E; Lou S; Koenke J; Shteyler V; Ikram K; Harding M; Bluth MH; Ng M; Brandt-Rauf PW; Hannan R; Bradu S; Zenilman ME; Michl J; Pincus MR
    Ann Surg Oncol; 2008 Dec; 15(12):3588-600. PubMed ID: 18931881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption.
    Krzesaj P; Adler V; Feinman RD; Miller A; Silberstein M; Yazdi E; Pincus MR
    Ann Clin Lab Sci; 2024 Mar; 54(2):137-148. PubMed ID: 38802154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.
    Sarafraz-Yazdi E; Bowne WB; Adler V; Sookraj KA; Wu V; Shteyler V; Patel H; Oxbury W; Brandt-Rauf P; Zenilman ME; Michl J; Pincus MR
    Proc Natl Acad Sci U S A; 2010 Feb; 107(5):1918-23. PubMed ID: 20080680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide.
    Sookraj KA; Bowne WB; Adler V; Sarafraz-Yazdi E; Michl J; Pincus MR
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):325-31. PubMed ID: 20182728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Targeting of H/MDM-2 Oncoprotein in Human Colon Cancer Cells and Stem-like Colonic Epithelial-derived Progenitor Cells.
    Thadi A; Morano WF; Khalili M; Babcock BD; Shaikh MF; Foster DS; Piazza Y; Gleeson EM; Goldstein E; Steele L; Campbell PM; Lin BO; Pincus MR; Bowne WB
    Anticancer Res; 2021 Jan; 41(1):27-42. PubMed ID: 33419797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis.
    Sarafraz-Yazdi E; Mumin S; Cheung D; Fridman D; Lin B; Wong L; Rosal R; Rudolph R; Frenkel M; Thadi A; Morano WF; Bowne WB; Pincus MR; Michl J
    Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo.
    Michl J; Scharf B; Schmidt A; Huynh C; Hannan R; von Gizycki H; Friedman FK; Brandt-Rauf P; Fine RL; Pincus MR
    Int J Cancer; 2006 Oct; 119(7):1577-85. PubMed ID: 16688716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-cancer peptides from ras-p21 and p53 proteins.
    Pincus MR; Fenelus M; Sarafraz-Yazdi E; Adler V; Bowne W; Michl J
    Curr Pharm Des; 2011; 17(25):2677-98. PubMed ID: 21728981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 c-terminal peptide in human pre-malignant and malignant cells.
    Li Y; Mao Y; Rosal RV; Dinnen RD; Williams AC; Brandt-Rauf PW; Fine RL
    Int J Cancer; 2005 May; 115(1):55-64. PubMed ID: 15645452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site.
    Do TN; Rosal RV; Drew L; Raffo AJ; Michl J; Pincus MR; Friedman FK; Petrylak DP; Cassai N; Szmulewicz J; Sidhu G; Fine RL; Brandt-Rauf PW
    Oncogene; 2003 Mar; 22(10):1431-44. PubMed ID: 12629507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rescue of K562 cells from MDM2-modulated p53-dependent apoptosis by growth factor-induced differentiation.
    Mahdi T; Alcalay D; Cognard C; Tanzer J; Kitzis A
    Biol Cell; 1998 Dec; 90(9):615-27. PubMed ID: 10085538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule MDM2 inhibitor LQFM030-induced apoptosis in p53-null K562 chronic myeloid leukemia cells.
    de Oliveira Ribeiro H; Cortez AP; de Ávila RI; da Silva ACG; de Carvalho FS; Menegatti R; Lião LM; Valadares MC
    Fundam Clin Pharmacol; 2020 Aug; 34(4):444-457. PubMed ID: 32011031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells.
    Rosal R; Pincus MR; Brandt-Rauf PW; Fine RL; Michl J; Wang H
    Biochemistry; 2004 Feb; 43(7):1854-61. PubMed ID: 14967026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell Membrane Composition Drives Selectivity and Toxicity of Designed Cyclic Helix-Loop-Helix Peptides with Cell Penetrating and Tumor Suppressor Properties.
    Philippe GJ; Gaspar D; Sheng C; Huang YH; Benfield AH; Condon ND; Weidmann J; Lawrence N; Löwer A; Castanho MARB; Craik DJ; Troeira Henriques S
    ACS Chem Biol; 2019 Sep; 14(9):2071-2087. PubMed ID: 31390185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer.
    Sarafraz-Yazdi E; Gorelick C; Wagreich AR; Salame G; Angert M; Gartman CH; Gupta V; Bowne WB; Lee YC; Abulafia O; Pincus MR; Michl J
    Ann Clin Lab Sci; 2015; 45(6):650-8. PubMed ID: 26663795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergy between Paclitaxel and Anti-Cancer Peptide PNC-27 in the Treatment of Ovarian Cancer.
    Alagkiozidis I; Gorelick C; Shah T; Chen YA; Gupta V; Stefanov D; Amarnani A; Lee YC; Abulafia O; Sarafraz-Yazdi E; Michl J
    Ann Clin Lab Sci; 2017 May; 47(3):271-281. PubMed ID: 28667027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.